

Global Ibritumomab Tiuxetan Production, Demand and Key Producers, 2022-2028

<https://marketpublishers.com/r/G50DC7CA9633EN.html>

Date: October 2022

Pages: 102

Price: US\$ 4,480.00 (Single User License)

ID: G50DC7CA9633EN

Abstracts

It is the world's first radiolabeled monoclonal antibody, launched in the United States in 2002 and approved for the treatment of refractory and relapsed B-cell non-Hodgkin's lymphoma. Radioimmunization represented by Zevalin marks a new era for human treatment of non-Hodgkin lymphoma. Zevalin combines the excellent targeting of monoclonal antibodies and the powerful radiotherapy effect of radioisotopes, so it can maximize the effect of radiotherapy. kill tumor cells.

This report studies the global Ibritumomab Tiuxetan demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Ibritumomab Tiuxetan, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2021 as the base year. This report explores demand trends and competition, as well as details the characteristics of Ibritumomab Tiuxetan that contribute to its increasing demand across many markets.

The global Ibritumomab Tiuxetan market size is expected to reach \$ million by 2028, rising at a market growth of % CAGR during the forecast period (2022-2028).

Highlights and key features of the study

Global Ibritumomab Tiuxetan total market, 2017-2028, (USD Million)

Global Ibritumomab Tiuxetan total market by region & country, CAGR, 2017-2028, (USD Million)

U.S. VS China: Ibritumomab Tiuxetan total market, key domestic companies and share, (USD Million)

Global Ibritumomab Tiuxetan revenue by player and market share 2017-2022, (USD Million)

Global Ibritumomab Tiuxetan total market by Concentration, CAGR, 2017-2028, (USD Million)

Global Ibritumomab Tiuxetan total market by Application, CAGR, 2017-2028, (USD Million)

This reports profiles major players in the global Ibritumomab Tiuxetan market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include CASI Pharmaceuticals, Biogen, Bayer, Spectrum, CSL Behring, Grifols, Baxalta, Octapharma and Kedrion, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Ibritumomab Tiuxetan market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Concentration, and by Application. Data is given for the years 2017-2028 by year with 2021 as the base year, 2022 as the estimate year, and 2028 as the forecast year.

Global Ibritumomab Tiuxetan Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Ibritumomab Tiuxetan Market, Segmentation by Concentration

0.05

0.25

Global Ibritumomab Tiuxetan Market, Segmentation by Application

Follicular Non-hodgkin Lymphoma

Metastatic B-cell Non-hodgkin Lymphoma

Companies Profiled:

CASI Pharmaceuticals

Biogen

Bayer

Spectrum

CSL Behring

Grifols

Baxalta

Octapharma

Kedrion

Key Questions Answered

1. How big is the global Ibritumomab Tiuxetan market?
2. What is the demand of the global Ibritumomab Tiuxetan market?
3. What is the year over year growth of the global Ibritumomab Tiuxetan market?
4. What is the total value of the global Ibritumomab Tiuxetan market?
5. Who are the major players in the global Ibritumomab Tiuxetan market?
6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

- 1.1 Ibritumomab Tiuxetan Introduction
- 1.2 World Ibritumomab Tiuxetan Market Size & Forecast (2017 & 2021 & 2028)
- 1.3 World Ibritumomab Tiuxetan Total Market by Region
 - 1.3.1 World Ibritumomab Tiuxetan Market Size by Region (2017-2028)
 - 1.3.2 United States Ibritumomab Tiuxetan Market Size (2017-2028)
 - 1.3.3 China Ibritumomab Tiuxetan Market Size (2017-2028)
 - 1.3.4 Europe Ibritumomab Tiuxetan Market Size (2017-2028)
 - 1.3.5 Japan Ibritumomab Tiuxetan Market Size (2017-2028)
 - 1.3.6 South Korea Ibritumomab Tiuxetan Market Size (2017-2028)
 - 1.3.7 ASEAN Ibritumomab Tiuxetan Market Size (2017-2028)
 - 1.3.8 India Ibritumomab Tiuxetan Market Size (2017-2028)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 Ibritumomab Tiuxetan Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 Ibritumomab Tiuxetan Major Market Trends
- 1.5 Influence of COVID-19 and Russia-Ukraine War
 - 1.5.1 Influence of COVID-19
 - 1.5.2 Influence of Russia-Ukraine War

2 WORLD IBRITUMOMAB TIUXETAN COMPANIES COMPETITIVE ANALYSIS

- 2.1 World Ibritumomab Tiuxetan Revenue by Player (2017-2022)
- 2.2 Industry Rank and Concentration Rate (CR)
 - 2.2.1 Global Ibritumomab Tiuxetan Industry Rank of Major Players
 - 2.2.2 Global Concentration Ratios (CR4) for Ibritumomab Tiuxetan in 2021
 - 2.2.3 Global Concentration Ratios (CR8) for Ibritumomab Tiuxetan in 2021
- 2.3 Ibritumomab Tiuxetan Company Evaluation Quadrant
- 2.4 Ibritumomab Tiuxetan Market: Overall Company Footprint Analysis
 - 2.4.1 Ibritumomab Tiuxetan Market: Region Footprint
 - 2.4.2 Ibritumomab Tiuxetan Market: Company Product Type Footprint
 - 2.4.3 Ibritumomab Tiuxetan Market: Company Product Application Footprint
- 2.5 Competitive Environment
 - 2.5.1 Historical Structure of the Industry
 - 2.5.2 Barriers of Market Entry
 - 2.5.3 Factors of Competition

2.6 Mergers, Acquisitions Activity

3 UNITED STATES VS CHINA VS REST OF THE WORLD

3.1 United States VS China: Ibritumomab Tiuxetan Market Comparison

3.1.1 United States VS China: Ibritumomab Tiuxetan Market Size Comparison (2017 & 2021 & 2028)

3.1.2 United States VS China: Ibritumomab Tiuxetan Market Size Market Share Comparison (2017 & 2021 & 2028)

3.2 United States Ibritumomab Tiuxetan Major Players and Market Share, 2017-2022

3.2.1 Major Players of Ibritumomab Tiuxetan in United States, Headquarters (States, Country)

3.2.2 United States Ibritumomab Tiuxetan Revenue by Domestic Player, (2017-2022)

3.3 China Ibritumomab Tiuxetan Major Players and Market Share, 2017-2022

3.3.1 Major Players of Ibritumomab Tiuxetan in China, Headquarters (Province, Country)

3.3.2 China Ibritumomab Tiuxetan Revenue by Domestic Player, (2017-2022)

3.4 Rest of World Ibritumomab Tiuxetan Major Players and Market Share, 2017-2022

3.4.1 Major Players of Ibritumomab Tiuxetan in Rest of World, Headquarters (State, Country)

3.4.2 Rest of World Ibritumomab Tiuxetan Revenue by Domestic Player, (2017-2022)

4 MARKET ANALYSIS BY CONCENTRATION

4.1 World Ibritumomab Tiuxetan Market Size Overview by Concentration: 2017 VS 2021 VS 2028

4.2 Segment Introduction by Concentration

4.2.1 0.05

4.2.2 0.25

4.3 Market Segment by Concentration

4.3.1 World Ibritumomab Tiuxetan Market Size by Concentration (2017-2022)

4.3.2 World Ibritumomab Tiuxetan Market Size by Concentration (2023-2028)

4.3.3 World Ibritumomab Tiuxetan Market Size Market Share by Concentration (2017-2028)

5 MARKET ANALYSIS BY APPLICATION

5.1 World Ibritumomab Tiuxetan Market Size Overview by Application: 2017 VS 2021 VS 2028

5.2 Segment Introduction by Application

5.2.1 Follicular Non-hodgkin Lymphoma

5.2.2 Metastatic B-cell Non-hodgkin Lymphoma

5.3 Market Segment by Application

5.3.1 World Ibritumomab Tiuxetan Market Size by Application (2017-2022)

5.3.2 World Ibritumomab Tiuxetan Market Size by Application (2023-2028)

5.3.3 World Ibritumomab Tiuxetan Market Size by Application (2017-2028)

6 COMPANY PROFILES

6.1 CASI Pharmaceuticals

6.1.1 CASI Pharmaceuticals Details

6.1.2 CASI Pharmaceuticals Major Business

6.1.3 CASI Pharmaceuticals Ibritumomab Tiuxetan Product and Services

6.1.4 CASI Pharmaceuticals Ibritumomab Tiuxetan Revenue, Gross Margin and Market Share (2017-2022)

6.1.5 CASI Pharmaceuticals Recent Developments/Updates

6.1.6 CASI Pharmaceuticals Competitive Strengths & Weaknesses

6.2 Biogen

6.2.1 Biogen Details

6.2.2 Biogen Major Business

6.2.3 Biogen Ibritumomab Tiuxetan Product and Services

6.2.4 Biogen Ibritumomab Tiuxetan Revenue, Gross Margin and Market Share (2017-2022)

6.2.5 Biogen Recent Developments/Updates

6.2.6 Biogen Competitive Strengths & Weaknesses

6.3 Bayer

6.3.1 Bayer Details

6.3.2 Bayer Major Business

6.3.3 Bayer Ibritumomab Tiuxetan Product and Services

6.3.4 Bayer Ibritumomab Tiuxetan Revenue, Gross Margin and Market Share (2017-2022)

6.3.5 Bayer Recent Developments/Updates

6.3.6 Bayer Competitive Strengths & Weaknesses

6.4 Spectrum

6.4.1 Spectrum Details

6.4.2 Spectrum Major Business

6.4.3 Spectrum Ibritumomab Tiuxetan Product and Services

6.4.4 Spectrum Ibritumomab Tiuxetan Revenue, Gross Margin and Market Share

(2017-2022)

6.4.5 Spectrum Recent Developments/Updates

6.4.6 Spectrum Competitive Strengths & Weaknesses

6.5 CSL Behring

6.5.1 CSL Behring Details

6.5.2 CSL Behring Major Business

6.5.3 CSL Behring Ibritumomab Tiuxetan Product and Services

6.5.4 CSL Behring Ibritumomab Tiuxetan Revenue, Gross Margin and Market Share

(2017-2022)

6.5.5 CSL Behring Recent Developments/Updates

6.5.6 CSL Behring Competitive Strengths & Weaknesses

6.6 Grifols

6.6.1 Grifols Details

6.6.2 Grifols Major Business

6.6.3 Grifols Ibritumomab Tiuxetan Product and Services

6.6.4 Grifols Ibritumomab Tiuxetan Revenue, Gross Margin and Market Share

(2017-2022)

6.6.5 Grifols Recent Developments/Updates

6.6.6 Grifols Competitive Strengths & Weaknesses

6.7 Baxalta

6.7.1 Baxalta Details

6.7.2 Baxalta Major Business

6.7.3 Baxalta Ibritumomab Tiuxetan Product and Services

6.7.4 Baxalta Ibritumomab Tiuxetan Revenue, Gross Margin and Market Share

(2017-2022)

6.7.5 Baxalta Recent Developments/Updates

6.7.6 Baxalta Competitive Strengths & Weaknesses

6.8 Octapharma

6.8.1 Octapharma Details

6.8.2 Octapharma Major Business

6.8.3 Octapharma Ibritumomab Tiuxetan Product and Services

6.8.4 Octapharma Ibritumomab Tiuxetan Revenue, Gross Margin and Market Share

(2017-2022)

6.8.5 Octapharma Recent Developments/Updates

6.8.6 Octapharma Competitive Strengths & Weaknesses

6.9 Kedrion

6.9.1 Kedrion Details

6.9.2 Kedrion Major Business

6.9.3 Kedrion Ibritumomab Tiuxetan Product and Services

6.9.4 Kedrion Ibritumomab Tiuxetan Revenue, Gross Margin and Market Share (2017-2022)

6.9.5 Kedrion Recent Developments/Updates

6.9.6 Kedrion Competitive Strengths & Weaknesses

7 RAW MATERIAL AND INDUSTRY CHAIN

7.1 Raw Material of Ibritumomab Tiuxetan and Key Manufacturers

7.2 Ibritumomab Tiuxetan Manufacturing Costs

7.3 Ibritumomab Tiuxetan Production Process

7.4 Ibritumomab Tiuxetan Industrial Chain

8 DISTRIBUTION CHANNEL ANALYSIS

8.1 Distribution Channel Breakdown for Ibritumomab Tiuxetan Shipments (%): 2017-2028

8.1.1 Direct Channel

8.1.2 Indirect Channel

8.2 Ibritumomab Tiuxetan Typical Distributors

8.3 Ibritumomab Tiuxetan Typical Customers

9 RESEARCH FINDINGS AND CONCLUSION

10 APPENDIX

10.1 Methodology

10.2 Research Process and Data Source

10.3 Disclaimer

List Of Tables

LIST OF TABLES

- Table 1. World Ibritumomab Tiuxetan Market Size by Region (2017, 2022 and 2028) & (USD Million)
- Table 2. World Ibritumomab Tiuxetan Market Size by Region (2017-2022) & (USD Million)
- Table 3. World Ibritumomab Tiuxetan Market Size by Region (2023-2028) & (USD Million)
- Table 4. World Ibritumomab Tiuxetan Market Size Market Share by Region (2017-2022)
- Table 5. World Ibritumomab Tiuxetan Market Size Market Share by Region (2023-2028)
- Table 6. Major Market Trends
- Table 7. World Ibritumomab Tiuxetan Revenue by Player (2017-2022) & (USD Million)
- Table 8. Revenue Market Share of Key Ibritumomab Tiuxetan Players in 2021
- Table 9. World Ibritumomab Tiuxetan Industry Rank of Major Player, Based on Revenue in 2021
- Table 10. Global Ibritumomab Tiuxetan Company Evaluation Quadrant
- Table 11. Head Office of Key Ibritumomab Tiuxetan Player
- Table 12. Ibritumomab Tiuxetan Market: Company Product Type Footprint
- Table 13. Ibritumomab Tiuxetan Market: Company Product Application Footprint
- Table 14. Ibritumomab Tiuxetan Mergers & Acquisitions Activity
- Table 15. United States VS China Ibritumomab Tiuxetan Market Size Comparison, (2017 & 2021 & 2028) & (USD Million)
- Table 16. Major Player of Ibritumomab Tiuxetan in United States, Headquarters (States, Country)
- Table 17. United States Ibritumomab Tiuxetan Revenue by Domestic Player, (2017-2022) & (USD Million)
- Table 18. United States Ibritumomab Tiuxetan Revenue Market Share by Domestic Player, (2017-2022)
- Table 19. Major Player of Ibritumomab Tiuxetan in China, Company Headquarters (Province, Country)
- Table 20. China Ibritumomab Tiuxetan Revenue by Domestic Player, (2017-2022) & (USD Million)
- Table 21. China Ibritumomab Tiuxetan Revenue Market Share by Domestic Player, (2017-2022)
- Table 22. Major Player of Ibritumomab Tiuxetan in Rest of World, Company Headquarters (State, Country)
- Table 23. Rest of World Ibritumomab Tiuxetan Revenue by Domestic Player,

(2017-2022) & (USD Million)

Table 24. Rest of World Ibritumomab Tiuxetan Revenue Market Share by Domestic Player, (2017-2022)

Table 25. World Ibritumomab Tiuxetan Revenue by Concentration, (USD Million), 2017 & 2021 & 2028

Table 26. World Ibritumomab Tiuxetan Revenue by Concentration (2017-2022) & (USD Million)

Table 27. World Ibritumomab Tiuxetan Revenue by Concentration (2023-2028) & (USD Million)

Table 28. World Ibritumomab Tiuxetan Revenue by Application, (USD Million), 2017 & 2021 & 2028

Table 29. World Ibritumomab Tiuxetan Revenue by Application (2017-2022) & (USD Million)

Table 30. World Ibritumomab Tiuxetan Revenue by Application (2023-2028) & (USD Million)

Table 31. CASI Pharmaceuticals Basic Information, Manufacturing Base and Competitors

Table 32. CASI Pharmaceuticals Major Business

Table 33. CASI Pharmaceuticals Ibritumomab Tiuxetan Product and Services

Table 34. CASI Pharmaceuticals Ibritumomab Tiuxetan Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 35. CASI Pharmaceuticals Recent Developments/Updates

Table 36. CASI Pharmaceuticals Competitive Strengths & Weaknesses

Table 37. Biogen Basic Information, Manufacturing Base and Competitors

Table 38. Biogen Major Business

Table 39. Biogen Ibritumomab Tiuxetan Product and Services

Table 40. Biogen Ibritumomab Tiuxetan Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 41. Biogen Recent Developments/Updates

Table 42. Biogen Competitive Strengths & Weaknesses

Table 43. Bayer Basic Information, Manufacturing Base and Competitors

Table 44. Bayer Major Business

Table 45. Bayer Ibritumomab Tiuxetan Product and Services

Table 46. Bayer Ibritumomab Tiuxetan Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)

Table 47. Bayer Recent Developments/Updates

Table 48. Bayer Competitive Strengths & Weaknesses

Table 49. Spectrum Basic Information, Manufacturing Base and Competitors

Table 50. Spectrum Major Business

Table 51. Spectrum Ibritumomab Tiuxetan Product and Services
Table 52. Spectrum Ibritumomab Tiuxetan Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 53. Spectrum Recent Developments/Updates
Table 54. Spectrum Competitive Strengths & Weaknesses
Table 55. CSL Behring Basic Information, Manufacturing Base and Competitors
Table 56. CSL Behring Major Business
Table 57. CSL Behring Ibritumomab Tiuxetan Product and Services
Table 58. CSL Behring Ibritumomab Tiuxetan Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 59. CSL Behring Recent Developments/Updates
Table 60. CSL Behring Competitive Strengths & Weaknesses
Table 61. Grifols Basic Information, Manufacturing Base and Competitors
Table 62. Grifols Major Business
Table 63. Grifols Ibritumomab Tiuxetan Product and Services
Table 64. Grifols Ibritumomab Tiuxetan Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 65. Grifols Recent Developments/Updates
Table 66. Grifols Competitive Strengths & Weaknesses
Table 67. Baxalta Basic Information, Manufacturing Base and Competitors
Table 68. Baxalta Major Business
Table 69. Baxalta Ibritumomab Tiuxetan Product and Services
Table 70. Baxalta Ibritumomab Tiuxetan Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 71. Baxalta Recent Developments/Updates
Table 72. Baxalta Competitive Strengths & Weaknesses
Table 73. Octapharma Basic Information, Manufacturing Base and Competitors
Table 74. Octapharma Major Business
Table 75. Octapharma Ibritumomab Tiuxetan Product and Services
Table 76. Octapharma Ibritumomab Tiuxetan Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 77. Octapharma Recent Developments/Updates
Table 78. Kedrion Basic Information, Manufacturing Base and Competitors
Table 79. Kedrion Major Business
Table 80. Kedrion Ibritumomab Tiuxetan Product and Services
Table 81. Kedrion Ibritumomab Tiuxetan Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 82. Ibritumomab Tiuxetan Raw Material
Table 83. Key Manufacturers of Ibritumomab Tiuxetan Raw Materials

Table 84. Ibritumomab Tiuxetan Typical Distributors

Table 85. Ibritumomab Tiuxetan Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Ibritumomab Tiuxetan Picture

Figure 2. World Ibritumomab Tiuxetan Total Market Size: 2017 & 2021 & 2028, (USD Million)

Figure 3. World Ibritumomab Tiuxetan Total Market Size (2017-2028) & (USD Million)

Figure 4. World Ibritumomab Tiuxetan Market Size Market Share by Region (2017-2028)

Figure 5. United States Ibritumomab Tiuxetan Market Size (2017-2028) & (USD Million)

Figure 6. China Ibritumomab Tiuxetan Market Size (2017-2028) & (USD Million)

Figure 7. Europe Ibritumomab Tiuxetan Market Size (2017-2028) & (USD Million)

Figure 8. Japan Ibritumomab Tiuxetan Market Size (2017-2028) & (USD Million)

Figure 9. South Korea Ibritumomab Tiuxetan Market Size (2017-2028) & (USD Million)

Figure 10. ASEAN Ibritumomab Tiuxetan Market Size (2017-2028) & (USD Million)

Figure 11. India Ibritumomab Tiuxetan Market Size (2017-2028) & (USD Million)

Figure 12. Ibritumomab Tiuxetan Market Drivers

Figure 13. Factors Affecting Demand

Figure 14. Producer Shipments of Ibritumomab Tiuxetan by Player Revenue (\$MM) and Market Share (%): 2021

Figure 15. Global Four-firm Concentration Ratios (CR4) for Ibritumomab Tiuxetan Markets in 2021

Figure 16. Global Four-firm Concentration Ratios (CR8) for Ibritumomab Tiuxetan Markets in 2021

Figure 17. United States VS China: Ibritumomab Tiuxetan Market Size Market Share Comparison (2017 & 2021 & 2028)

Figure 18. World Ibritumomab Tiuxetan Market Size by Concentration, (USD Million), 2017 & 2021 & 2028

Figure 19. World Ibritumomab Tiuxetan Market Size Market Share by Concentration in 2021

Figure 20. 0.05

Figure 21. 0.25

Figure 22. World Ibritumomab Tiuxetan Market Size Market Share by Concentration (2017-2028)

Figure 23. World Ibritumomab Tiuxetan Market Size by Application, (USD Million), 2017 & 2021 & 2028

Figure 24. World Ibritumomab Tiuxetan Market Size Market Share by Application in 2021

Figure 25. Follicular Non-hodgkin Lymphoma

Figure 26. Metastatic B-cell Non-hodgkin Lymphoma

Figure 27. World Ibritumomab Tiuxetan Market Size Market Share by Application (2017-2028)

Figure 28. Manufacturing Cost Structure Analysis of Ibritumomab Tiuxetan in 2021

Figure 29. Manufacturing Process Analysis of Ibritumomab Tiuxetan

Figure 30. Ibritumomab Tiuxetan Industrial Chain

Figure 31. Distribution Channel Breakdown for Ibritumomab Tiuxetan Shipments (%): 2017-2028

Figure 32. Direct Channel Pros & Cons

Figure 33. Indirect Channel Pros & Cons

Figure 34. Methodology

Figure 35. Research Process and Data Source

I would like to order

Product name: Global Ibritumomab Tiuxetan Production, Demand and Key Producers, 2022-2028

Product link: <https://marketpublishers.com/r/G50DC7CA9633EN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G50DC7CA9633EN.html>